Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

Despite the widebody makeover and new Vossen alloys, this pre-facelifted Rolls-Royce Cullinan is still very appealing. Dig ...

Rolls-Royce has announced the sales results for 2024 alongside a £300 million ($373 million) investment for the expansion of ...

Best Buy will move out of its long time location in Peoria and move to The Levee District in East Peoria, Cullinan Properties ...

East Peoria's Levee District is one of the Peoria region's busier hubs for retail and dining and is also the location for a ...

Those involved with England at the 2003 World Cup will feel a sense of unease at history repeating itself as the pressure ...

Rolls-Royce ( BMW.DE) CEO Chris Brownridge, like many other importers, is wary of President-elect Donald Trump's plans to ...

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.

CLN-049 is under clinical development by Cullinan Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Here is everything to know about Rolls Royce Cullinan Series II, the facelifted Rolls Royce SUV. Design, specifications, features and more.

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.